

Two New Categories for Part B Step Therapy Program 2023 Updates for Medicare Advantage Members

Florida Blue Medicare added two categories to the Part B step therapy program affecting Medicare Advantage members effective January 1, 2023.

Drug Alternatives

Step therapy requires authorization for certain higher-cost medications. We encourage you to consider prescribing a preferred alternative instead of the non-preferred drugs as noted in the charts below.

Complement Inhibitors

Preferred Product(s)		Indication	Non-preferred Product	
Ultomiris Vyvgart	J1303 J9332	Myasthenia gravis (gMG)	Soliris	J1300
Empaveli Ultomiris	C9399 J1303	Paroxysmal nocturnal hemoglobinuria (PNH)		
Ultomiris	J1303	Hemolytic uremic syndrome, atypical (aHUS)		
Enspryng Uplinza	C9399 J1823	Neuromyelitis optica spectrum disorder (NMOSD)		
Step therapy does not apply for other orphan indications, only medical necessity criteria for Soliris as per Centers for Medicare & Medicaid Services guidance.		Other orphan indications: dermatomyositis, shiga-toxin producing E.Coli HUS, idiopathic membranous glomerular nephropathy, prevention of delayed graft rejection in renal transplant		

Viscosupplements

Preferred Product(s)		Non-preferred Products	
Synvisc/Synvisc One Orthovisc	J7325	Durolane	J7318
		Euflexxa	J7323
		Gel-One	J7326
		Gelsyn-3	J7328
		Genvisc-850	J7320
		Hyalgen	J7321
		Hymovis	J7322
		Monovisc	J7327
		Supartz	J7321
		Supartz FX	J7321
Triluron	J7332		
Visco-3	J7321		

Note: Step therapy will only be applied to new prescriptions or administrations of Part B drugs for enrollees who are not actively receiving the affected medication.

Florida Blue Medicare is an Independent Licensee of the Blue Cross and Blue Shield Association.